来自圣安东尼奥德克萨斯大学健康科学中心（UT Health San Antonio）的一组科学家发现了一种治疗急性髓性白血病（AML）的新药靶点。根据美国国家癌症研究所的数据，急性髓性白血病是一种致命的血癌，5年生存率仅为30%。他们的研究发表在2月份的《细胞干细胞 ...

A graphic showing, top to bottom, how DNA aptamers target two specific markers on a leukemia stem cell’s surface, enter the cell and deliver anticancer drugs, resulting in death of the cancer cell.

CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nature Cancer , 2025; DOI: 10.1038/s43018-025-00934-1 Cite ...

The researchers looked at stem cells from AML patients at the Stanford Medical Center to see if they also expressed CD47. “They all did,” says Weissman. After demonstrating in cell culture experiments ...

However, approximately one in three patients with AML relapse after allogenic stem cell transplant. DLI is a follow-on ...

Allogenic hematopoietic stem cell transplant is an important therapy for AML patients. In 2024 alone, 20,800 new cases of AML were diagnosed and the five-year survival rate for patients is 31.9% ...

Novel CAR T cells and cord blood-derived CAR NK cells for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. When a patient with KG2032-reactive AML ...

The cell therapy company’s lead product, Carvykti, is a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson JNJ.

The treatment is designed to be more effective, safer and easier to dose than traditional allogeneic stem cell transplants against a range of leukemias. Cancer therapy developer Orca Bio hopes to ...